Britain Courts Anthropic Amid US Defense Department Dispute 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Apple Turns 50: From Garage Startup to AI Crossroads 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
- Webcast to be held Thursday, October 6, 2016 at 11:00 a.m. ET
STAMFORD, Conn., Oct. 03, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and Chief Executive Officer, will participate in a webcast featuring innovations in pain management therapies. The webcast is part of a series from Biopharma Dealmakers, a quarterly supplement in Nature Biotechnology and Nature Reviews Drug Discovery.
Four companies that are working to address unmet needs in pain management will present their developments, which include analgesics with novel mechanisms of action, medical devices, and opioids with reduced potential for abuse and physical dependence. The webcast will also include a roundtable discussion and a question and answer session with Dr. Chalmers and the other speakers.
Details for the webcast are as follows:
Date: Thursday, October 6, 2016
Time: 11:00 a.m. ET
Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers
Participants:
- Dr. Derek Chalmers, President and CEO of Cara Therapeutics
- Dr. Jeffrey Herz, President and CEO of Algomedix, Inc.
- Dr. Jessica Preciado, Director of Product Development and Principal Scientist of Myoscience
- Dr. Steve Doberstein, Senior Vice President and Chief Scientific Officer of Nektar Therapeutics
For more information, and to register for this free webcast, visit: http://www.workcast.com/register?cpak=5922214840089056&referrer=SPONSOR_CaraTherapeutics.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
